Publications by authors named "Martin Bornhauser"

Claim this Profile
P
Prognostic Value of Multicolor-Flow Cytometric Measurable Residual Disease Detection in Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation: Potential Role of HLA-DR.
Maximilian A Röhnert, Chiara Löffler, Michael Kramer, Christoph Röllig, Johannes Schetelig

Clin Lymphoma Myeloma Leuk· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.
Katja Sockel, Christoph Röllig, Anke Mütherig, Martina Crysandt, Sven Zukunft

Am J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis.
Wentao Gui, Petr Paral, Bhavuk Dhamija, Eman Hagag, Martin Dusa

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia.
Klaus Wethmar, Matthias Edinger, Kerstin Schäfer-Eckart, Matthias Stelljes, Thomas Schroeder

Bone Marrow Transplant· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
Anne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, Katja Sockel, Rebekka Wehner

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Image-based explainable artificial intelligence accurately identifies myelodysplastic neoplasms beyond conventional signs of dysplasia.
Jan-Niklas Eckardt, Ishan Srivastava, Freya Schulze, Susann Winter, Tim Schmittmann

NPJ Precis Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction.
Kavitha Lakshmi, Alexandra von Jutrzenka-Trzebiatowski, Liliana Loureiro, Karla Elizabeth González Soto, Katja Peter

J Transl Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.
Cornelius Pauli, Michael Kienhöfer, Maximilian Felix Blank, Oguzhan Begik, Christian Rohde

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings.
Johannes Schetelig, Henning Baldauf, Carina Rave, Gesine Bug, Lutz P Müller

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
Uwe Platzbecker, Lionel Adès, Pau Montesinos, Emanuele Ammatuna, Pierre Fenaux

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML.
Uta Oelschlaegel, Jonas Schadt, Katharina Epp, Lisa Wagenführ, Leo Ruhnke

Hemasphere· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia.
Sandra Küchler, Silke Brilloff, Silvia Schäfer, Elahe Rahimian, Vida Kufrin

Cell Death Discov· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.
Marius Bill, Jan-Niklas Eckardt, Konstanze Döhner, Maximillian-Alexander Röhnert, Christian Rausch

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment.
Julian Ronnacker, Leo Ruhnke, Christoph Röllig, Jan Moritz Middeke, Regina Herbst

Leukemia· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.
Julian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch, Sven Zukunft, Barbora Weinbergerová

Leukemia· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness of allogeneic bone marrow-derived mesenchymal stromal cell therapy for complex perianal and rectovaginal fistulas in Crohn's disease: a retrospective case series.
Julia Husman, Margarete Wardenga, Sophie Kirk, Katja Matthes, Bernd Naumann

BMJ Open Gastroenterol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled analysis of 3 large multicenter trials confirms a survival advantage for AML in MRD remission after intensive induction.
Konstanze Döhner, Hartmut Döhner, Daniela Späth, Silke Kapp-Schwoerer, Amanda Gilkes

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A quiescence-like/TGF-β1-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML.
Elahe Rahimian, Masoud Koochak, Sofia Traikov, Michael Schroeder, Silke Brilloff

Drug Resist Updat· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Sara Tarantino, Myriam Labopin, Robert Zeiser, Matthias Stelljes, Thomas Schroeder

Bone Marrow Transplant· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.
Lydia Kretschmer, Leo Ruhnke, Christoph Schliemann, Lars Fransecky, Björn Steffen

Ann Hematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protective effects for HLA-B*40:01 and C*03:04 in NPM1-mutated AML: result of a large HLA association study.
Elke Rücker-Braun, Bose Falk, Henning Baldauf, Carolin Massalski, Gesine Schäfer

Front Immunol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AML.
Jan-Niklas Eckardt, Waldemar Hahn, Rhonda E Ries, Szymon D Chrost, Susann Winter

Hemasphere· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compassionate Use of Osocimab in Preventing Thrombotic Complications Without Incremental Bleeding: A Case Report.
Jan Beyer-Westendorf, Katrin Weber, Falk Eckart, Martin W Laass, Ralf Knöfler

TH Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients.
Christina Rautenberg, Jan Moritz Middeke, Christoph Röllig, Matthias Stelljes, Verena Gaidzik

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis